Great post @vijayghelani. Well said. A few facts, (some may not...

Great post @vijayghelani. Well said.

A few facts, (some may not be joyful reading for us holders):

1. $3.8 billion AUD (£2bn) had been spent on the [covid] testing system in January in the UK alone. Let that sink in. ~$4bn, in one month, in one country, which isn't in the top 20 in terms of population size.
2. I have been talking for some time about a long tail downward trend in demand for Covid testing. This means that there may still be demand for a product like EuGeni (for Covid), however at a fraction of the scale that has been seen over the past 2 years. England today has announced that as of 1 April '22 "Free mass testing for symptomatic and asymptomatic for the general public will end". Other countries will most likely follow suit. The downtrend for testing has started. Medium term and we'll see the long tail IMO.
3. I asked the ADO board 18 months ago - "what is your approach to commercialisation?" In hindsight, the silence that I was met with on a number of occasions was most likely because they did not know how. I suggested hiring a Sales & Marketing Director - here we are, at the tail end of the pandemic having not made any proper sales (due to a number of reasons - but mostly relating to the lack of Go To Market strategy and execution of one). I took some shares off the table at 40c to derisk last May solely due to a lack of confidence in GTM strategy.
4. The Flu A/B Multiplex opportunity missed by AnteoTech took my confidence away from the AnteoTech leadership team. There are a number of key differences between a company like Quidel and AnteoTech. But I'll just call out an obvious one - both companies stated that they were going to release a Multiplex Flu A/B & Covid test for the N Hemisphere 21/22 flu season. Quidel have had their product in market since September '21. AnteoTech (Derek) had stated (on 25 March 2021) that Clinical Trials were due to start Sept 2021. We are now at the end of the N Hemisphere flu season and the recent 4C (31 January 2022) stated that "The multiplex (COVID, Flu A/B) will move to prototype development, with the aim of preparing R&D batches in Feb 2022". In summary Quidel made lots of money and AnteoTech are preparing R&D batches while the Flu season ends.
5. We are approaching EuGeni's 1 year anniversary since launch. Doesn't matter what industry you are in, what geography you target or operate in etc.. If you have not been able to commercialise product - there is usually something or some things wrong. How long until we get the next TGA update? >150 days since our first TGA submission.

We need answers from the ADO Leadership. And swiftly. Hopefully @vijayghelani's post has been noticed and Derek + team act. Comms has been woeful (and I am not only referring to the embarrassing 4C submission that had errors from start to finish).

A lot of holders are shifting focus to batteries. Let's hope that the GTM strategy is solid and ADO have learned from EuGeni. But then, I come back to my point 18 months ago - where is the Sales and Marketing Director for this business?!